Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 2/20 | 0.70 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.70 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16870888 | 0.81 | PTPN7 (0.47) | PLA2G1BATG4BPOLBLMNAKMT2A | |
| SCHEMBL15100298 | 0.81 | SMN1; SMN2 (0.53) | POLBLMNAKMT2AHPGDMEN1 | |
| SCHEMBL20496874 | 0.80 | PLA2G1B (0.78) | PLA2G1BATG4BMAOBPOLBLMNA | |
| SCHEMBL6621549 | 0.80 | PLA2G1B (0.66) | PLA2G1BATG4BMAOBPOLBLMNA | |
| SCHEMBL2530016 | 0.79 | KMT2A (0.63) | PLA2G1BATG4BMAOBPOLBLMNA | |
| SCHEMBL16216177 | 0.79 | PLA2G1B (0.59) | PLA2G1BATG4BMAOBPOLBLMNA | |
| SCHEMBL1959781 | 0.79 | PLA2G1B (0.70) | PLA2G1BATG4BMAOBPOLBLMNA | |
| SCHEMBL12657500 | 0.79 | PLA2G1B (0.59) | PLA2G1BATG4BMAOBLMNAKMT2A | |
| SCHEMBL2451899 | 0.78 | ALOX12 (0.68) | PLA2G1BATG4BMAOBPOLBLMNA | |
| SCHEMBL4872149 | 0.77 | PTPN7 (0.53) | PLA2G1BATG4BPOLBLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1436249-B1 | MUSCARINIC AGONISTS | LILLY CO ELI (US) | 2013-11-06 | — | — | EP | disclosed |
| US-7326731-B2 | Muscarinic agonists | ELI LILLY AND COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| CN-1556788-A | Muscarinic agonists | — | 2004-12-22 | — | — | CN | disclosed |
| US-20040242584-A1 | exemplified by Biphenyl-4-carboxylic acid (R)-(6-(1-((4-fluorobenzyl)methylamino)ethylideneamino) 2(R)-hydroxyindan-1-yl)amide; treating cognitive impairment associated with schizophrenia or Alzheimer's disease | ELI LILLY AND COMPANY | 2004-12-02 | — | — | US | disclosed |
| EP-1436249-A2 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003027061-A2 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242584-A1 | exemplified by Biphenyl-4-carboxylic acid (R)-(6-(1-((4-fluorobenzyl)methylamino)ethylideneamino) 2(R)-hydroxyindan-1-yl)amide; treating cognitive impairment associated with schizophrenia or Alzheimer's disease | CHRM1, CHRM2, CHRM4 | PLA2G1B 1758/4885ATG4B 4107/4885MAOB 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.